Please login to the form below

Not currently logged in
Email:
Password:

Transition halts diabetes drug development

Transition Therapeutics has discontinued development of a new therapy for type 2 diabetes after it failed to meet efficacy endpoints

Transition Therapeutics has discontinued development of a potential new therapy for type 2 diabetes after it failed to meet the efficacy endpoints in a late-stage clinical study. The drug, gastrin analogue TT-223, was being tested in combination with a GLP-1 analogue that Transition licensed from Lilly.

"While TT-223 has shown efficacy through development, these results indicate that it does not have the product profile for a diabetes therapy," the company said.

The randomised, double-blind study enroled 150 patients who received either a placebo regimen or daily doses of TT-223 in combination with weekly doses of GLP-1 analogue for four weeks. The study also included a five-month follow-up period.

Transition said its broad in-licensing and collaboration agreement with Lilly will not be affected by the termination of the TT-223 development programme. The deal, which was announced in March of this year, gives Transition exclusive worldwide rights to a series of Lilly's pre-clinical drug candidates for diabetes and related co-morbid conditions. Lilly retains the option to re-acquire the rights to the compounds later in their development.

The Lilly drugs represent a new class of compounds that, in pre-clinical diabetes models, showed potential to provide glycaemic control and weight loss.

The deal signed this year built on a pre-existing partnership between the two companies in the area of gastrin-based therapies for diabetes developed by Transition. That collaboration, which was formed in 2008, granted Lilly exclusive worldwide rights to develop and commercialise Transition's gastrin based therapies, including TT-223.

Toronto-based Transition does not yet have any marketed products. Its lead product in development is a phase III drug for Alzheimer's disease.

21st September 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Viseven

Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...